Sandler Alan B. 的 Form 4 申報
Revolution Medicines, Inc.（RVMD），2026/10/1 申報
- 申報編號
- 0001835966-26-000008
- 申報時間
- 2026/10/1 18:00 ET
- 交易日
- 2026/9/29
- 申報延遲
- 2 天
- 10b5-1 計畫
- 有勾選
這份申報列了 6 筆非衍生性交易、1 筆衍生性交易。公開市場賣出合計 $127.5 萬。交易後 2 天申報。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Sandler Alan B.CIK 0001835966 | 高階主管（發展長） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/9/29 | Common Stock | M行使選擇權取得 | +6,000 | $58.84 | +$353,040 | 58,868 | 直接 | |
| 2026/9/29 | Common Stock | S賣出處分 | −2,200 | $200.82F2 | −$441,801.36 | 56,668 | 直接 | |
| 2026/9/29 | Common Stock | S賣出處分 | −1,609 | $201.72F3 | −$324,573.76 | 55,059 | 直接 | |
| 2026/9/29 | Common Stock | S賣出處分 | −1,000 | $202.81F4 | −$202,812.7 | 54,059 | 直接 | |
| 2026/9/29 | Common Stock | S賣出處分 | −1,199 | $203.91F5 | −$244,484.97 | 52,860 | 直接 | |
| 2026/9/29 | Common Stock | S賣出處分 | −301 | $204.72F6 | −$61,621.44 | 52,559 | 直接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2026/9/29 | Common Stock | M行使選擇權處分 | −167,300 | $0.00 | $0 | 161,300 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F2
The transaction was executed in multiple trades at prices ranging from $200.41 to $201.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The transaction was executed in multiple trades at prices ranging from $201.41 to $202.16, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F4
The transaction was executed in multiple trades at prices ranging from $202.42 to $203.34, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F5
The transaction was executed in multiple trades at prices ranging from $203.42 to $204.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
- F6
The transaction was executed in multiple trades at prices ranging from $204.43 to $204.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。